On Monday, CytomX Therapeutics Inc (NASDAQ: CTMX) opened higher 19.85% from the last session, before settling in for the closing price of $0.80. Price fluctuations for CTMX have ranged from $0.40 to $5.06 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 36.21% annually for the last half of the decade. Company’s average yearly earnings per share was noted -58.68% at the time writing. With a float of $78.13 million, this company’s outstanding shares have now reached $80.10 million.
In an organization with 121 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 99.03%, operating margin of 18.1%, and the pretax margin is 23.24%.
CytomX Therapeutics Inc (CTMX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of CytomX Therapeutics Inc is 2.46%, while institutional ownership is 58.09%. The most recent insider transaction that took place on Mar 18 ’25, was worth 22,556. In this transaction CEO of this company sold 37,656 shares at a rate of $0.60, taking the stock ownership to the 995,195 shares. Before that another transaction happened on Mar 18 ’25, when Company’s Chief Financial Officer sold 8,551 for $0.60, making the entire transaction worth $5,122. This insider now owns 201,026 shares in total.
CytomX Therapeutics Inc (CTMX) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.08 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -58.68% per share during the next fiscal year.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
Check out the current performance indicators for CytomX Therapeutics Inc (CTMX). In the past quarter, the stock posted a quick ratio of 1.25. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.56.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.39, a number that is poised to hit 0.12 in the next quarter and is forecasted to reach -0.60 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
Let’s dig in a bit further. During the last 5-days, its volume was 2.06 million. That was better than the volume of 1.73 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 87.84%. Additionally, its Average True Range was 0.08.
During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 63.77%, which indicates a significant decrease from 90.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 114.63% in the past 14 days, which was higher than the 92.52% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6448, while its 200-day Moving Average is $0.9786. However, in the short run, CytomX Therapeutics Inc’s stock first resistance to watch stands at $1.0264. Second resistance stands at $1.0917. The third major resistance level sits at $1.1833. If the price goes on to break the first support level at $0.8695, it is likely to go to the next support level at $0.7779. The third support level lies at $0.7126 if the price breaches the second support level.
CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats
There are currently 80,621K shares outstanding in the company with a market cap of 76.99 million. Presently, the company’s annual sales total 138,100 K according to its annual income of 31,870 K. Last quarter, the company’s sales amounted to 38,090 K and its income totaled 18,880 K.
